Compare Centrus Energy Corp (LEU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Centrus Energy Corp trades at $117.04 (market cap $2.75B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Centrus Energy Corp is far larger — about 2.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 31 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LEU | MRVI | |
|---|---|---|
Market Cap | $2.75B | $972.90M |
Volume | 573,041 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $436.00 | $9.00 |
52-Week Low | $119.95 | $2.83 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.06B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with $448.70M revenue and $77.80M net income for 2025, though profitability declined in 2026. Recent multi-year HALEU supply contracts with Antares and Radiant highlight Centrus' strategic position in the nuclear fuel market as the only US-licensed HALEU producer.
The stock presents a compelling growth opportunity in nuclear energy infrastructure with 46% analyst buy ratings and $218.10 consensus price target, but faces execution risks amid high valuation multiples (P/E 71.05) and recent earnings volatility. Key risks include dependency on nuclear policy support and competitive pressures in uranium enrichment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
